Peptide · Approved

Bremelanotide

A melanocortin-receptor agonist (Vyleesi, PT-141) for low sexual desire in premenopausal women.

Key facts

  • Also known as: Vyleesi, PT-141
  • Status: Approved
  • Used for: Low sexual desire (HSDD)
  • Natural counterpart: Mimics α-MSH, the natural melanocortin hormone.
  • Target enzyme / receptor: Melanocortin receptors (mainly MC4R) — GPCRs
  • Signalling pathway: Gαs → cAMP in CNS pathways governing sexual response
    In plain terms: Activates brain melanocortin pathways involved in sexual desire.
  • Crystal / cryo-EM structure: Available  PDB 7PIU ↗

Status & safety

This is an approved medicine — prescription-only in most countries. Only use it under a licensed clinician, obtained through a pharmacy.

Research & clinical studies

Explore the biochemistry and clinical evidence for Bremelanotide — these open live, date-sorted searches, so they always show the latest.

Read research papers on PubMed ↗

Clinical studies (ClinicalTrials.gov) ↗ Google Scholar ↗ Related guide → All peptides & profiles →

Not medical advice. Chemdu is an educational resource and does not sell, prescribe or supply any peptide. Consult a licensed professional about any medicine or supplement.